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Abstract 
Objectives 
To describe pathways of care and referral to paediatric rheumatology from onset of 
first symptom (noticed by the patient or their family) to diagnosis for children and 
young people diagnosed with localised scleroderma (LS) or juvenile systemic 
sclerosis (jSSc).  
Methods 
Retrospective case note audit of patients under paediatric rheumatology care who 
presented January 2005 – January 2010. Data included: Disease subtype, sex, age 
at key points in the referral pathway and health care professional (HCP) contact. All 
patient and HCP data was pseudo-anonymised in accordance with good clinical 
practice.  
Results 
Data from eight UK centres saw 89 cases: 62 female, 26 male; 73 LS, 16 jSSc. 
Median time from first symptom to first HCP review: 4 (range 0-72) months (LS) and 
1 (range 0-50) month (jSSc). Median time from first symptom to paediatric 
rheumatology review: 15 (range 1-103) months (LS) and 7 (range 0-50) months 
(jSSc). Median time from first HCP review to first paediatric rheumatology review: 11 
(range 0-103) months (LS) and 2 (range 0-10) months. First HCP seen was usually 
(74%) a General Practitioner (GP). Referring HCP to paediatric rheumatology was 
usually a dermatologist (56%) for LS. Median time from first symptom to diagnosis: 
13 (range 1-102) months (LS) and 8 (range 1-50) months (jSSc).  
Conclusions 
! &!
A prolonged interval occurs from first symptom to definitive diagnosis which may 
adversely affect outcome. There is a need to raise awareness of this rare diagnosis 
and facilitate earlier recognition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! '!
Introduction 
Scleroderma in childhood has two distinct groupings: localised scleroderma (LS) and 
the much rarer juvenile systemic sclerosis (jSSc). Both LS and jSSc are very rare 
paediatric diseases (estimated incidences per million of 3.4 and 0.27 respectively[1]) 
Diagnosis and classification[2,3] of LS and jSSc are essentially clinical. There is no 
universal consensus of classification criteria for use in clinical practice or clinical 
trials. LS is differentiated from jSSc based upon clinical findings of almost exclusive 
cutaneous involvement. Recent reports have documented a higher rate of extra-
cutaneous manifestations (approaching 25%) than previously thought in LS leading 
to calls for earlier multi-system investigation and more aggressive treatment in those 
with widespread disease.[4] 
The pathogenesis of scleroderma is complex and remains poorly understood. 
Excessive collagen deposition and autoimmune dysfunction seem to be key factors 
and small-vessel vasculopathy also appears to play a role in jSSc.[5,6] Optimal 
treatment is controversial due largely to a lack of high quality clinical trials. Most 
paediatric rheumatologists advocate systemic immunosuppression in a significant 
proportion of cases to avoid organ damage (particularly in jSSc[7,8]), progressive 
deformity, functional disability, and disfigurement.[9,10] Corticosteroids, methotrexate 
and etanercept are widely used and case reports document use of other biologic 
therapies.  
In the United Kingdom (UK) there is no consensus regarding optimal management 
for children and young people with scleroderma. It is well recognised that optimal 
management of complex, rare conditions involves concentrating expertise within 
specialist centres and shared care with local centres as appropriate – this model is 
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strongly advocated within the British Society for Paediatric and Adolescent 
Rheumatology (BSPAR) Standards of Care for children and young people with 
Juvenile Idiopathic Arthritis (JIA).[11] Consequently many children and young people 
with scleroderma in the UK are managed by paediatric rheumatology 
multidisciplinary teams (MDTs) in collaboration with colleagues in dermatology or 
paediatrics. Pathways through which children and young people reach these teams 
are often complex; a recently published UK prospective cohort reporting incidence 
data received notifications from paediatric and adult dermatologists (44%), paediatric 
and adult rheumatologists (31%) and paediatricians (25%).[1] 
The aim of this study was to describe care pathways and the involvement of health 
care professionals (HCPs) in these pathways. Anecdotally, children and young 
people with scleroderma may present to various HCPs working in primary care and 
hospital services, and experience a complex and often protracted pathway before the 
diagnosis is confirmed and appropriate treatment commenced. These care pathways 
have not previously been investigated; this study aims to provide an initial 
assessment and, it is anticipated, will inform the development of strategies to 
facilitate earlier recognition and triage to optimal care.   
Methods 
A retrospective case note audit was performed and included patients under 
paediatric rheumatology care at the time of the study and who presented between 
January 2005 – January 2010. Data was collected using pre-tested pro formas 
piloted in three centres. Data collated included the age when first symptom noticed, 
age when first seen by HCP (and description of HCP involved), age when first 
referred to paediatric rheumatology, age when first seen by paediatric rheumatology 
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and when the diagnosis was first entered into the medical record (by any HCP). In 
each case, age was recorded in years and months.  Further information was 
collected regarding LS and jSSc subtypes; pro forma A (LS) included the anatomical 
location, depth and size of skin lesion at presentation (if recorded in the medical 
record). Anecdotal evidence suggests significant variation in methods used to 
evaluate skin lesions (depth, size and inflammatory activity) in UK paediatric 
rheumatology centres. Collecting and analysing this data was beyond the scope of 
this project however further detailed work is planned to investigate how this 
information is collected in the UK. Pro forma B (jSSc) included information regarding 
evidence of organ system involvement (as documented in the medical record) prior 
to assessment at a paediatric rheumatology centre and at diagnosis. In current UK 
paediatric rheumatology practice, anecdotal evidence suggests clinicians do not 
consistently use a standardised protocol for assessing organ system involvement. 
We therefore chose to focus on expert clinician assessment rather than potentially 
exclude a significant proportion of cases considering the rarity of jSSc.  
All data (patient, HCP and centre) was pseudo-anonymised and collected in 
accordance with good clinical practice.[12] The study was deemed an audit of clinical 
care and exempted from ethical approval. Only UK training centres were invited to 
participate and cases were only included where diagnosis had been established by 
expert paediatric rheumatologist opinion. Paediatric rheumatology trainees who had 
attended the BSPAR annual trainee meeting (Bristol UK, November 2009) collected 
the data under supervision by their responsible consultant paediatric rheumatologist. 
Results 
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Eight centres provided data on 89 cases (73 LS, 16 jSSc). The majority were females 
(overall 62/89, 70%; within the LS group 49/73, 67%; within the jSSc group 13/16, 
81%). The median number of cases per centre was 9.5 (range 2 - 22). Participating 
centres consisted only of representative UK tertiary teaching paediatric rheumatology 
centres. 
Classification for LS cases (at time of study) was as follows: Linear scleroderma, 49 
cases (67%); plaque morphea, 8 cases (11%); general morphea 6 cases (8%); 
Parry-Romberg, 1 case (1%); multiple subtypes, 3 cases (4%); unspecified, 2 cases 
(3%); not recorded, 3 cases (4%). Lesion depth at diagnosis (as documented in the 
medical record) was as follows: Dermis, 1 case (1%); subcutaneous, 10 cases 
(14%); Fascia, 3 cases (4%); muscle, 6 cases (8%); bone, 0 cases (0%); joint, 5 
cases (7%), not recorded, 42 cases (58%). Of the 73 LS cases, 6 reported other 
system involvement: 1 autoimmune hepatitis, 1 arthritis, 2 central nervous system 
involvement (1 headaches, 1 unspecified), 1 ocular involvement and 1 an associated 
leg-length discrepancy. Associations were based on specialist paediatric 
rheumatology opinion as recorded in the medical record. From data collected 
however, it was not possible to differentiate between co-morbidities and true 
associations.  
Table 1 summarises HCP first seen and referring HCP and compares LS with jSSc 
cases. Table 2a summarises the key stages in the care pathway and Table 2b 
summarises intervals between the key stages in the care pathway. Table 2a also 
summarises missing data, which was proportionally represented across LS and jSSc 
cases.  
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In most cases (74%) the first HCP seen was a general practitioner (GP). The HCP 
referring to paediatric rheumatology was usually a dermatologist (56%) for LS, and 
varied for jSSc. The median number of HCPs seen prior to referral to paediatric 
rheumatology was 2 (range 1 - 5). The diagnosis was usually made at a similar time 
to first review by a paediatric rheumatologist however, in some cases the diagnosis 
was made either significantly earlier or later to first review in paediatric rheumatology 
services (Table 2b). Data was not collected regarding physician making the 
diagnosis.   
Discussion 
This is the largest series of patients with childhood onset LS and jSSc to focus on 
access to paediatric rheumatology care. We demonstrate a protracted interval from 
observed onset of symptoms to diagnosis and furthermore a prolonged interval to 
access to the paediatric rheumatology MDT. In a disease such as scleroderma, 
where inadequate treatment can lead to deformity and disability, such prolonged 
intervals are likely to adversely affect outcomes.  
We acknowledge that this study has a number of limitations. Firstly, we only recruited 
patients under paediatric rheumatology care which is likely to reflect bias towards 
more severe disease, and may represent a different clinical spectrum of scleroderma 
to that observed in dermatology care (where children with seemingly mild disease 
may never be referred to paediatric rheumatology services).  
Secondly, there was no predetermined standard method for case ascertainment by 
participating centres. Some, but not all, centres had clinical databases. In some 
centres cases were recalled from memory of the team members, introducing 
potential recall bias. Given that the total number of cases contributed by each 
! ""!
participating centre was small, reflecting the rarity of the disease, we would suggest 
recall of individual patients is likely to be accurate.  
Thirdly, this was a retrospective analysis of case notes which likely introduced further 
bias in terms of the accuracy of the written documentation. Notably there was 
missing data observed in several case notes as described.  
Fourthly, there is no universally accepted diagnostic test for scleroderma, making 
verification of case ascertainment challenging; furthermore there is no consensus on 
diagnostic criteria for LS and the American College of Rheumatology (ACR) criteria 
for jSSc have been shown to be insensitive.[13] The 2007 proposed diagnostic 
criteria[3] for jSSc were not available at the start of the audit and, whilst useful, are 
not universally accepted in clinical practice or clinical trials. We therefore took a 
pragmatic approach to accept the clinical diagnosis documented by a consultant 
paediatric rheumatologist or dermatologist.  The first documentation of the diagnosis 
was made in most cases by a paediatric rheumatologist at the initial assessment 
although in LS cases more diagnoses were made by a dermatologist, reflecting 
differing pathways of care.  
Given these biases and limitations, it is noteworthy that the age at which symptoms 
were first noticed (by the child, young person or their family), and the time between 
disease onset and first review by a paediatric rheumatologist was similar to other 
published retrospective and prospective cohorts.[1,14,15] suggesting that this patient 
group is representative.   
Consensus amongst paediatric rheumatologists is that jSSc and most LS lesions 
require systemic immunosuppression and MDT input; in LS this is especially 
important if lesions are recent, multiple, or involving face or limb as such lesions can 
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be disfiguring and potentially disabling. Many such cases were observed in this 
cohort. It is therefore likely that patients with more severe disease are likely to benefit 
most from early systemic immunosuppressive therapy aimed at minimising 
irreversible damage and functional loss. Therefore the observed protracted interval to 
confirmation of diagnosis and starting treatment is important and may adversely 
affect long term outcome. 
This study demonstrates that receiving an early diagnosis and obtaining access to 
specialist care are important challenges to improving outcomes for children with 
these rare conditions. It is noteworthy that some of the protracted interval arises from 
delay from first symptom to first HCP visit and referral to paediatric rheumatology. 
This suggests need to raise public awareness as well as awareness among primary 
care physicians and paediatricians, to consider scleroderma earlier and refer patients 
for specialist opinion.  
Conclusion 
This study suggests pathways to care are complex and involve many HCPs. We 
have observed a protracted interval from time of first symptom onset to diagnosis 
and referral to paediatric rheumatology. Access to care is therefore a major 
challenge when considering improving outcomes for children and young people 
receiving a diagnosis of scleroderma. Further work is required to raise awareness of 
this rare diagnosis, facilitate earlier recognition and referral to specialist services. 
Key Messages 
1. Children with localised scleroderma face complex pathways to care which 
involve many health care professionals. 
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2. A protracted interval exists between first symptom and referral to paediatric 
rheumatology services. 
3. Accessing care is a major challenge when considering improving outcomes for 
children with localised scleroderma. 
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